MX2017011910A - Métodos, herramientas y sistemas para la evaluación, prevención, manejo y selección de tratamiento para diabetes tipo 2. - Google Patents

Métodos, herramientas y sistemas para la evaluación, prevención, manejo y selección de tratamiento para diabetes tipo 2.

Info

Publication number
MX2017011910A
MX2017011910A MX2017011910A MX2017011910A MX2017011910A MX 2017011910 A MX2017011910 A MX 2017011910A MX 2017011910 A MX2017011910 A MX 2017011910A MX 2017011910 A MX2017011910 A MX 2017011910A MX 2017011910 A MX2017011910 A MX 2017011910A
Authority
MX
Mexico
Prior art keywords
type
diabetes
assessment
tools
prevention
Prior art date
Application number
MX2017011910A
Other languages
English (en)
Inventor
Simon Buela Laureano
G Zulueta Mirella
Original Assignee
Patia Biopharma S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Patia Biopharma S A De C V filed Critical Patia Biopharma S A De C V
Publication of MX2017011910A publication Critical patent/MX2017011910A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención provee un método para evaluar la susceptibilidad a la diabetes tipo 2 y/o predecir la respuesta al tratamiento en un sujeto humano, el que comprende determinar la identidad de al menos un alelo en cada una de tres o más posiciones de polimorfismo de nucleótido simple (SNP) seleccionadas del grupo que consiste en: SLC16A11 - rs75493593, HNF1A - rs483353044; TCF7L2 - rs7903146, CDKN2A/B - rs10811661, CDKAL1 - rs7756992, SLC30A8 - rs3802177, IGF2BP2 - rs4402960, FTO - rs9936385, PPARG - rs1801282, HHEX/IDE - rs1111875, ADCY5 - rs11717195, JAZF1 - rs849135, WSF1 - rs4458523, INS-IGF2 - rs149483638, KCNQ1 - rs2237897 y KCNJ11 - rs5219, y/o un SNP con desequilibrio de enlace con cualquiera de dichos SNP a r2>0.8. También se proveen una herramienta de genotipado y un sistema de evaluación de riesgo de diabetes tipo 2 a utilizar en el método de la invención.
MX2017011910A 2015-03-18 2016-03-18 Métodos, herramientas y sistemas para la evaluación, prevención, manejo y selección de tratamiento para diabetes tipo 2. MX2017011910A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1504607.1A GB201504607D0 (en) 2015-03-18 2015-03-18 Methods,tools and systems for the assessment,preventation,management and treatment selection for type 2 diabetes
PCT/EP2016/055949 WO2016146811A1 (en) 2015-03-18 2016-03-18 Methods, tools and systems for the assessment, prevention, management and treatment selection for type 2 diabetes

Publications (1)

Publication Number Publication Date
MX2017011910A true MX2017011910A (es) 2018-08-28

Family

ID=53052023

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011910A MX2017011910A (es) 2015-03-18 2016-03-18 Métodos, herramientas y sistemas para la evaluación, prevención, manejo y selección de tratamiento para diabetes tipo 2.

Country Status (8)

Country Link
US (2) US20180094318A1 (es)
EP (1) EP3271476B1 (es)
JP (1) JP6751418B2 (es)
DK (1) DK3271476T3 (es)
ES (1) ES2794950T3 (es)
GB (1) GB201504607D0 (es)
MX (1) MX2017011910A (es)
WO (1) WO2016146811A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019237209A1 (en) * 2018-06-15 2019-12-19 Opti-Thera Inc. Polygenic risk scores for predicting disease complications and/or response to therapy
JP6688418B1 (ja) * 2019-04-16 2020-04-28 ジェネシスヘルスケア株式会社 ２型糖尿病のリスクを判定する方法
WO2021170504A1 (en) * 2020-02-25 2021-09-02 Ling Charlotte Dna methylation level of specific cpg sites for prediction of glycemic response and tolerance to metformin treatment in type 2 diabetic patients
CN113393896A (zh) * 2021-06-11 2021-09-14 成都果壳医学科技有限公司 一种基于深度神经网络的i型糖尿病风险评估系统
WO2024080651A1 (ko) * 2022-10-12 2024-04-18 서울대학교병원 Thada 마커를 이용한 설폰요소제 의존성 예측용 조성물 및 그 예측 방법
KR20240051814A (ko) * 2022-10-12 2024-04-22 서울대학교병원 Gipr 마커를 이용한 설폰요소제 의존성 예측용 조성물 및 그 예측 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6210272B1 (en) 1997-12-22 2001-04-03 Health Hero Network, Inc. Multi-player interactive electronic game for health education
JP5033392B2 (ja) 2006-03-10 2012-09-26 国立大学法人三重大学 ２型糖尿病の遺伝的リスク検出法
US20090307180A1 (en) 2008-03-19 2009-12-10 Brandon Colby Genetic analysis
NZ598009A (en) * 2009-07-10 2013-11-29 Decode Genetics Ehf Genetic markers associated with risk of diabetes mellitus

Also Published As

Publication number Publication date
EP3271476B1 (en) 2020-03-04
US20200318192A1 (en) 2020-10-08
US20180094318A1 (en) 2018-04-05
WO2016146811A1 (en) 2016-09-22
JP6751418B2 (ja) 2020-09-09
ES2794950T3 (es) 2020-11-19
US11578368B2 (en) 2023-02-14
EP3271476A1 (en) 2018-01-24
GB201504607D0 (en) 2015-05-06
JP2018515128A (ja) 2018-06-14
DK3271476T3 (da) 2020-06-08

Similar Documents

Publication Publication Date Title
MX2017011910A (es) Métodos, herramientas y sistemas para la evaluación, prevención, manejo y selección de tratamiento para diabetes tipo 2.
CY1125362T1 (el) Διαχωρισμος γονιδιωματικων κλασματων με χρηση των μετρησεων πολυμορφισμων
WO2014116729A3 (en) Haplotying of hla loci with ultra-deep shotgun sequencing
WO2015200701A3 (en) Software haplotying of hla loci
GB2477868A (en) Methods and systems for incorporating multiple environmental and genetic risk factors
SG10201804519RA (en) Methods and systems for detecting genetic variants
WO2008089465A3 (en) Gene polymorphisms as sex-specific predictors in cancer therapy
WO2015006643A3 (en) Systems, methods, and environment for automated review of genomic data to identify downregulated and/or upregulated gene expression indicative of a disease or condition
MX2022013015A (es) Sistemas y metodos de uso para utilizar en la identificacion de multiples ediciones genomicas y predecir los efectos acumulados de las ediciones genomicas identificadas.
WO2008088893A3 (en) Gene polymorphisms in vegf and vegf receptor 2 as markers for cancer therapy
WO2020132499A3 (en) Systems and methods for using fragment lengths as a predictor of cancer
MX2010005060A (es) Identificacion y mapeo a base de microarreglos de adn de puntos de ruptura de translocacion equilibrados.
WO2006028999A3 (en) Assessment of ctla-4 polymorphisms in ctla-4 blockade therapy
WO2016176451A3 (en) System and method for processing genotype information relating to nsaid risk
WO2005112568A3 (en) Haplotype markers and methods of using the same to determine response to treatment
Zhou et al. The association between ANXA11 gene polymorphisms and sarcoidosis: a meta-analysis and systematic review
WO2011146788A3 (en) Methods of assessing a risk of developing necrotizing meningoencephalitis
MX2016012718A (es) Determinación de polimorfismos de un solo nucleótido útil para predecir la respuesta para rasagilina.
EP3315613A3 (en) Methods and kits for diagnosing or assessing the risk of cervical cancer
RU2014110824A (ru) Способ прогнозирования риска невынашивания первой половины беременности
AR104348A1 (es) Polimorfismos de un solo nucleótido seleccionados que son predictivos de respuestas al acetato de glatirámero
WO2006099329A3 (en) Method of analyzing breast cancer susceptibility and resistance
WO2016176475A3 (en) System and method for processing genotype information relating to opioid response
Bragantini Dopamine D2 receptor C957T polymorphism and its phenotypic consequences on executive functions in 8 years old children
RU2017120897A (ru) Способ прогнозирования резистентности

Legal Events

Date Code Title Description
FG Grant or registration